Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Something big is likely in the works

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jan 08, 2022 12:18am

191 Views

Post# 34295649

RE:RE:RE:RE:RE:RE:RE:Something big is likely in the works

TH has spoken about Chinese interest in partnerring in cancer, is seeking a partner in NASH and mentioned "inbound interest" on cancer, presumably from Western pharma companies. These are the most likely scenarios but there could be many others too, including scenarios with bad news or mixed news. Some limited restructuring might be possible (sell Trogarzo rights to Viiv, rename the company??) but it is hard to see anything really massive on that front. Also, the desire is to have a higher share price before an offering. I don't think they would be gauging shareholder interest in any strategic move they are contemplating.